Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models From acslX to Berkeley Madonna, MATLAB, and R Language: Oxytetracycline and Gold Nanoparticles As Case Examples.

Many physiologically based pharmacokinetic (PBPK) models for environmental chemicals, drugs, and nanomaterials have been developed to aid risk and safety assessments using acslX. However, acslX has been rendered sunset since November 2015. Alternative modeling tools and tutorials are needed for future PBPK applications. This forum article aimed to: (1) demonstrate the performance of 4 PBPK modeling software packages (acslX, Berkeley Madonna, MATLAB, and R language) tested using 2 existing models (oxytetracycline and gold nanoparticles); (2) provide a tutorial of PBPK model code conversion from acslX to Berkeley Madonna, MATLAB, and R language; (3) discuss the advantages and disadvantages of each software package in the implementation of PBPK models in toxicology, and (4) share our perspective about future direction in this field. Simulation results of plasma/tissue concentrations/amounts of oxytetracycline and gold from different models were compared visually and statistically with linear regression analyses. Simulation results from the original models were correlated well with results from the recoded models, with time-concentration/amount curves nearly superimposable and determination coefficients of 0.86-1.00. Step-by-step explanations of the recoding of the models in different software programs are provided in the Supplementary Data. In summary, this article presents a tutorial of PBPK model code conversion for a small molecule and a nanoparticle among 4 software packages, and a performance comparison of these software packages in PBPK model implementation. This tutorial helps beginners learn PBPK modeling, provides suggestions for selecting a suitable tool for future projects, and may lead to the transition from acslX to alternative modeling tools.

[1]  Annie Lumen,et al.  Evaluation of iodide deficiency in the lactating rat and pup using a biologically based dose-response model. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  M. Jamei,et al.  PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.

[3]  N Parrott,et al.  Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.

[4]  C. Delahunt,et al.  The distribution of tetracyclines in tissues of dogs after repeated oral administration. , 1966, The Journal of pharmacology and experimental therapeutics.

[5]  D. Mattie,et al.  Extrapolation of Hypothalamic-Pituitary-Thyroid Axis Perturbations and Associated Toxicity in Rodents to Humans: Case Study with Perchlorate , 2012, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[6]  E. Mitema,et al.  The Pharmacokinetics of a Long-acting Oxytetracycline Formulation in Healthy Dogs and in Dogs Infected with Ehrlichia canis , 2001, Veterinary Research Communications.

[7]  E. Robinson.  Cybernetics, or Control and Communication in the Animal and the Machine , 1963 .

[8]  George Loizou,et al.  Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.

[9]  Karline Soetaert,et al.  Inverse Modelling, Sensitivity and Monte Carlo Analysis in R Using Package FME , 2010 .

[10]  Sheila Annie Peters.  Modeling in the Pharmaceutical Industry , 2012 .

[11]  Mark G. Robson,et al.  Risk Assessment for Environmental Health , 2013 .

[12]  Yeyejide A. Adeleye,et al.  Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment. , 2015, Toxicology.

[13]  Charles A Timchalk,et al.  A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. , 2013, Regulatory toxicology and pharmacology : RTP.

[14]  J. Dormand,et al.  A family of embedded Runge-Kutta formulae , 1980 .

[15]  Anna M. Fan,et al.  The Application of PBPK Modeling, the Bayesian Approach, and the Utilization of Markov Chain Monte Carlo Simulation in Risk Assessment , 2015 .

[16]  Lawrence F. Shampine,et al.  The MATLAB ODE Suite , 1997, SIAM J. Sci. Comput..

[17]  Jim E Riviere,et al.  A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice , 2015, Nanotoxicology.

[18]  Frédéric Y. Bois,et al.  GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models , 2009, Bioinform..

[19]  Ronny Blust,et al.  Lifetime PCB 153 bioaccumulation and pharmacokinetics in pilot whales: Bayesian population PBPK modeling and Markov chain Monte Carlo simulations. , 2014, Chemosphere.

[20]  Jim E Riviere,et al.  A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles. , 2016, Nanomedicine.

[21]  Jeffrey Fisher,et al.  Translational Research to Develop a Human PBPK Models Tool Kit—Volatile Organic Compounds (VOCs) , 2012, Journal of toxicology and environmental health. Part A.

[22]  Karline Soetaert,et al.  Solving Differential Equations in R: Package deSolve , 2010 .

[23]  A. Fan,et al.  Toxicology and risk assessment , 2015 .

[24]  A. Immelman,et al.  Oxytetracycline plasma levels in dogs after intramuscular administration of two formulations. , 1981, Journal of the South African Veterinary Association.

[25]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[26]  R. Gehring,et al.  Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment. , 2016, Journal of veterinary pharmacology and therapeutics.

[27]  Annie Lumen,et al.  Evaluation of perturbations in serum thyroid hormones during human pregnancy due to dietary iodide and perchlorate exposure using a biologically based dose-response model. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  Chung-Min Liao,et al.  Physiologically based pharmacokinetic modeling of zinc oxide nanoparticles and zinc nitrate in mice , 2015, International journal of nanomedicine.

[29]  Markus Krauss,et al.  Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations , 2015, PloS one.

[30]  Hugh A Barton,et al.  Approaches for Applications of Physiologically Based Pharmacokinetic Models in Risk Assessment , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[31]  Jerry L. Campbell,et al.  PBPK-Based Probabilistic Risk Assessment for Total Chlorotriazines in Drinking Water , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[32]  Harvey J Clewell,et al.  The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. , 2007, Regulatory toxicology and pharmacology : RTP.

[33]  R. Yeary,et al.  The excretion and distribution in body fluids of tetracyclines after intravenous administration to dogs. , 1963, The Journal of pharmacology and experimental therapeutics.

[34]  Moiz M Mumtaz,et al.  Applications of computational toxicology methods at the Agency for Toxic Substances and Disease Registry. , 2002, International journal of hygiene and environmental health.

[35]  E Sidney Hunter,et al.  Species extrapolation of life-stage physiologically-based pharmacokinetic (PBPK) models to investigate the developmental toxicology of ethanol using in vitro to in vivo (IVIVE) methods. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  F Y Bois,et al.  Population toxicokinetics of benzene. , 1996, Environmental health perspectives.

[37]  Jim E Riviere,et al.  Pharmacokinetics of metallic nanoparticles. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[38]  M. Andersen,et al.  Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  Arthur N. Mayeno,et al.  Computational Toxicology of Chloroform: Reverse Dosimetry Using Bayesian Inference, Markov Chain Monte Carlo Simulation, and Human Biomonitoring Data , 2008, Environmental health perspectives.

[40]  Matematik,et al.  Numerical Methods for Ordinary Differential Equations: Butcher/Numerical Methods , 2005 .

[41]  Charles Timchalk,et al.  A human life-stage physiologically based pharmacokinetic and pharmacodynamic model for chlorpyrifos: development and validation. , 2014, Regulatory toxicology and pharmacology : RTP.

[42]  S. Peters.  Physiologically‐Based Pharmacokinetic Modeling of Populations , 2012 .

[43]  A. Craigmill.  A physiologically based pharmacokinetic model for oxytetracycline residues in sheep. , 2003, Journal of veterinary pharmacology and therapeutics.

[44]  Z. Zeng,et al.  Estimating marbofloxacin withdrawal time in broiler chickens using a population physiologically based pharmacokinetics model. , 2014, Journal of veterinary pharmacology and therapeutics.

[45]  B. Blount,et al.  Application of Physiologically Based Pharmacokinetic Models in Chemical Risk Assessment , 2012, Journal of toxicology.

[46]  Harvey J Clewell,et al.  Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  John F. Young,et al.  Development of a Physiologically Based Model to Describe the Pharmacokinetics of Methylphenidate in Juvenile and Adult Humans and Nonhuman Primates , 2014, PloS one.

[48]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[49]  L L Aylward,et al.  Application of pharmacokinetic modelling for 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure assessment£ , 2014, SAR and QSAR in environmental research.

[50]  J. Fisher,et al.  A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse. , 2011, Toxicology and applied pharmacology.

[51]  Jeffrey Fisher,et al.  Development of a Human Physiologically Based Pharmacokinetic (PBPK) Toolkit for Environmental Pollutants , 2011, International journal of molecular sciences.

[52]  Harvey J Clewell,et al.  Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[53]  A. Immelman.  Blood levels of oxytetracycline in dogs after oral administration. , 1977, Journal of the South African Veterinary Association.

[54]  Jianghong Fan,et al.  Physiologically Based Pharmacokinetic Modeling of Nanoparticles. , 2019, Journal of pharmaceutical sciences.

[55]  J. Riviere,et al.  Use of Probabilistic Modeling within a Physiologically Based Pharmacokinetic Model To Predict Sulfamethazine Residue Withdrawal Times in Edible Tissues in Swine , 2006, Antimicrobial Agents and Chemotherapy.

[56]  M. Andersen,et al.  A biologically based dose-response model for dietary iodide and the hypothalamic-pituitary-thyroid axis in the adult rat: evaluation of iodide deficiency. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[57]  J W Fisher,et al.  A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. , 1998, Toxicology and applied pharmacology.

[58]  Kristin Stamyr,et al.  Physiologically based pharmacokinetic modeling of hydrogen cyanide levels in human breath , 2015, Archives of Toxicology.

[59]  R. Gehring,et al.  Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. , 2015, Journal of pharmaceutical sciences.

[60]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[61]  Robert J Kavlock,et al.  Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[62]  H A el-Masri,et al.  The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures. , 1995, Toxicology letters.

[63]  C. Liao,et al.  Assessing exposure risks for freshwater tilapia species posed by mercury and methylmercury , 2016, Ecotoxicology.

[64]  Beom Soo Shin,et al.  PHYSIOLOGICALLY BASED PHARMACOKINETICS OF BISPHENOL A , 2004, Journal of toxicology and environmental health. Part A.

[65]  Zhoumeng Lin,et al.  Human Food Safety Implications of Variation in Food Animal Drug Metabolism , 2016, Scientific Reports.

[66]  Melvin E. Andersen,et al.  Physiologically Based Pharmacokinetic Modeling : Science and Applications , 2005 .

[67]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[68]  Melvin E. Andersen,et al.  PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[69]  C. Marzolini,et al.  Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies , 2015, Expert opinion on drug metabolism & toxicology.

[70]  S. Casteel,et al.  Biodistribution of maltose and gum arabic hybrid gold nanoparticles after intravenous injection in juvenile swine. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[71]  Zachary J. Thompson.  Statistical Estimation of Physiologically-based Pharmacokinetic Models: Identifiability, Variation, and Uncertainty with an Illustration of Chronic Exposure to Dioxin and Dioxin-like-compounds. , 2012 .

[72]  Harvey J Clewell,et al.  Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. , 2012, Reproductive toxicology.

[73]  M E Andersen,et al.  Physiologically based pharmacokinetics and cancer risk assessment. , 1994, Environmental health perspectives.

[74]  Harvey J. Clewell,et al.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse , 2014, Environmental health perspectives.

[75]  R. Cooke,et al.  Bioavailability of oxytetracycline dihydrate tablets in dogs. , 1981, Journal of veterinary pharmacology and therapeutics.

[76]  J. Fisher,et al.  Estimation of placental and lactational transfer and tissue distribution of atrazine and its main metabolites in rodent dams, fetuses, and neonates with physiologically based pharmacokinetic modeling. , 2013, Toxicology and applied pharmacology.

[77]  M. Fink,et al.  Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. , 2016, Journal of veterinary pharmacology and therapeutics.

[78]  B. A. Fowler,et al.  SAR and QSAR in Environmental Research , 2010 .

[79]  Jeffrey W Fisher,et al.  Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A. , 2015, Toxicology and applied pharmacology.

[80]  H. E. Buist,et al.  Characterization and application of physiologically based pharmacokinetic models in risk assessment , 2010 .

[81]  Anna C. Salzberg,et al.  Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead , 2015, Carcinogenesis.

[82]  M. Roberts,et al.  Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles. , 2016, Nano letters.

[83]  Stefan Rayer,et al.  Population forecast accuracy: does the choice of summary measure of error matter? , 2007 .

[84]  J. Molnar,et al.  Physiologically Based Pharmacokinetic Modeling???Science and Applications , 2006 .